

## Diagnostik immunologisch bedingter Thrombozytopenien

- 1) Djulbegovic B, Cohe Y:  
*The natural history of refractory idiopathic thrombocytopenic purpura.*  
*Blood*; **98**: 2282-2283 (2001).
- 2) Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B:  
*The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.*  
*Arch Intern Med*; **160**: 1630-1638 (2000).
- 3) Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A.  
*Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.*  
*Blood*; **97**:2549-2554 (2001).
- 5) Matzdorff A, Giagounidis A, Müller-Beißenhirtz H.  
*Immunthrombozytopenie.*  
*Leitlinie der DGHO* (2010).
- 6) Barrett JC, Call SA, Arndt DW, Dudley KA, Mahan JA, Saleh MN.  
*Thrombocytopenia with platelet-associated IgM antibodies: patient characteristics and responsiveness to IPT therapy.*  
*Blood*; **92 (Suppl. 1)**: 82b (1998).
- 7) Kiefel V, Santoso S, Weisheit M.  
*Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet reactive antibodies.*  
*Blood*; **70**: 1722-1726 (1987).
- 8) Meyer O, Agaylan A, Kiesewetter H, Salama A.  
*A novel antigen-specific capture assay for the detection of platelet antibodies and HPA-1a phenotyping.*  
*Vox Sang*; **91**: 324-330 (2006).
- 9) McFarland JG, Collins J, Aster RH, Moghaddam M, Bussel J.  
*Evaluation of a platelet glycoprotein (GP) specific assay in the diagnosis of autoimmune thrombocytopenia.*  
*Blood*; **94 (Suppl. 1)**: 15a (1999).
- 10) Lozano ML, Curtis BR, Hansen RM, Bayliss K, Petersen JA, Aster RH.  
*A GP IIb/IIIa-specific autoantibody from a patient with acquired amegakaryocytic thrombocytopenia appears to be the first example of a human ligand mimetic immunoglobulin.*  
*Blood*; **92 (Suppl. 1)**: 175a (1998).
- 11) Olsson B, Andresson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H.  
*T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.*  
*Nat Med*; **9**: 1123-1124 (2003).
- 12) Alimardani G, Guichard J, Fichelson S, Cramer EM.  
*Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets.*  
*Thromb Haemost*; **88**: 1039-1046 (2002).
- 13) Chang M, Nakagawa PA, Williams SA, Schartz MR, Imfeld KL, Buzby JS, Nugent DJ.  
*Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro.*  
*Blood*; **102**: 887-895 (2003).
- 14) McMillan R, Wang L, Tomer A, Nichol J, Pistillo J.  
*Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.*  
*Blood*; **103**: 1364-1369 (2004).

- 15) Emmons RC, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR:  
*Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction.*  
*Blood*; **87**: 4068-4071 (1996).
- 16) Nichol JL et al.  
*Stem Cells* **16**: 165-175 (1998).
- 17) Kuter DJ et al.  
*Efficiency of romiplostim in patients with chronic immune thrombocytopenic purpura. A double-blind randomized control trial.*  
*Lancet* **371**: 395-403 (2008).
- 18) Semple JW.  
*ITP three R's: regulation, routing, rituximab.*  
*Blood*; **112**: 927-928 (2008).
- 19) Li X, Zhong J, Bao W, Bould N, Bussel JB, Yasdanbakhsh K.  
*Regulatory B Cell Defects In Patient With Immune Thrombocytopenia (ITP).*  
*Blood*; **116 (Suppl)**: 171, Abstr. # 379 (2010).
- 20) Dickerhoff R, Ebert W.  
*Immunthrombozytopenie im Kindes- und Jugendalter, Leitlinie (2011).*
- 21) Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O:  
*Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia.*  
*Throm Haemost*; **100**: 762-765 (2008).
- 22) Kickler T, Braine H, Piantados S, Ness PM, Herman JH, Rothko K. A.  
*randomized, placebo-controlled trial of tranvenous gammaglobulin in alloimmunized thrombocytopenic patients.*  
*Blood*; **75**: 313-316 (1990).
- 23) Lee EJ, Norris D, Schiffer CA.  
*Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion.*  
*Transfusion*; **27**: 245-247 (1987).
- 26) Bussel, Kaplan C,  
*The fetal and neonatal consequences of maternal alloimmune thrombocytopenia.*  
*Baillière's Clinical Haematology*; **11**: 391-408 (1998).
- 28) Mueller-Eckhardt C, Förster C, Kayser W, Mueller-Eckhardt G, Frisch H, Grips M, Kachel W, Kobel H-F, von Kires R, Mutz I, Schönwetter M.  
*Alloimmunthrombozytopenie der Neugeborenen durch thrombozytenspezifische Antikörper (Anti-PIA1).*  
*Deutsche Medizinische Wochenschrift*; **107**, 216-219 (1982).
- 29) Mueller-Eckhardt C, Kiefel V, Grubert A, Kroll H, Weisheit M, Schmidt S, Mueller-Eckhardt G, Santoso S.  
*348 cases of suspected neonatal alloimmune thrombocytopenia.*  
*Lancet*; **I**, 363-366 (1989).
- 30) Williamson LM, Hackett G, Rennie J, Plamer CR, Maciver C, Hadfield R, Hughes D, Jobson S, Ouwehand WH.  
*The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PIA1, Zwa) as determined by antenatal screening.*  
*Blood*; **92**, 2280-2287 (1998).
- 31) Kroll H, Kiefel V, Santoso S  
*Clinical aspects and typing of platelet alloantigens*  
*VOX Sanguinis*; **74 (suppl 2)**, 345-354 (1998).

- 36) Kroll H, Yates J, Santoso S.  
*Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens.*  
*Transfusion*; 45, 353-358 (2005).
- 38) Greinacher A, Amiral J, Dummel Vissac A, Kiefel V, Mueller-Eckhardt C.  
*Laboratory diagnosis of heparin-associated thrombocytopenia and comparison platelet aggregation test, heparin induced activation test and platelet factor 4/heparin enzyme-linked immunosorbent assay.*  
*Transfusion*; 34:381-385 (1994).
- 41) Kroll H, Kiefel V, Giers G, Bald R, Hoch J, Hanfland P, Hansmann M, Müller-Eckhardt C.  
*Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia.*  
*Transfusion Medicine*; 4, 293-296 (1994).
- 42) Zalneraitis EL, Young RSK, Krishnamoorthy KS.  
*Intracranial hemorrhage in utero as a complication of isoimmune thrombocytopenia.*  
*J Pediatr*; 95, 611-614 (1979).
- 43) Kiefel V, Bassler D, Kroll H, Paes, Giers G, Ditomasso J, Alber H, Bers M, Wiebe B, Quenzel EM, Hoch J, Greinacher A.  
*Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT).*  
*Blood*; 107: 3761-3763 (2006).
- 44) Mueller-Eckhardt C, Kroll H, Kiefel V:  
*Posttransfusions purpura.* In: Kaplan-Gouet C, editor. *Platelet immunology: fundamental and clinical aspects.*  
John Libbey Eurotext 249-255 (1991).
- 45) Watkins NA, Smethurst PA, Allen D, Smith GA, Ouwehand WH:  
*Platelet alphaIIb-beta3 recombinant autoantibodies from the B-cell repertoire of a post-transfusion purpura patient.*  
*Br J Haematol*; 116: 677-685 (2002).
- 46) Kroll H, Kiefel V, Müller-Eckhardt C,  
*Posttransfusionelle purpura: klinische und immunologische Untersuchung bei 38 Patienten.*  
*Infusionstherapie und Transfusionsmedizin*; 20:198-204 (1993).
- 47) Kiefel.  
*Transfusionsmedizin und Immunhämatologie – Grundlagen, Therapie, Methodik, 4. Auflage; Springer Verlag Berlin (2010).*
- 48) Mueller-Eckhardt C, Kiefel V:  
*High-dose IgG for post-transfusion purpura revisited.*  
*Blut* 57: 163-167 (1988).
- 49) Anderson D, Ali K, Blanchette C, et al.:  
*Guidelines on the use of intravenous immune globulins for hematologic conditions.*  
*Transfus Med Rev*; 21: 9-56 (2007).
- 50) Gerstner JB, Smith MJ, Davis KD, Cimo PL, Aster RH:  
*Posttransfusion purpura: therapeutic failure of P1A1-negative platelet transfusion.*  
*Am Hematol*; 6: 71-75 (1979).
- 51) Howard JE, Perkins HA.  
*The natural history of alloimmunization to platelets.*  
*Transfusion*; 18: 496-503 (1978).
- 52) Murphy MF, Waters AH.  
*Immunological aspects of platelet transfusions.*  
*Br J Haematol*; 60: 409-414 (1985).

- 53) Slichter SJ, Mechanisms and management of platelet refractoriness. In: Nance ST, editor, *Transfusion medicine in the 1990's*, Arlington. AABB; 95-179 (1990).
- 54) Heal JM, Masel D, Rowe JM, et al. Circulating immune complexes involving the ABO system after platelet transfusion. *Br J Haematol*; **85**: 566-572 (1993).
- 55) Schnaidt M, Norhoff H, Wernet D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic disorders. *Transfus Med*; **6**: 111-114 (1996).
- 56) Delafior-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. *Transfus Med. Rev*; **14**: 180-196 (2000).
- 57) Langenscheid F, Kiefel V, Santoso S, Mueller-Eckhardt C. Platelet transfusion refractoriness associated with two rare platelet-specific alloantibodies (Anti-Bak(a) and anti-PI(A2)) and multiple HLA-antibodies. *Transfusions*; **28**: 597-600 (1988).
- 58) Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. *J Thromb Haemost*; **7**: 322-329 (2009).
- 59) Kiefel V, Santoso S. Alloantigene auf Thrombozyten. In Mueller-Eckhardt C, Kiefel V. *Transfusionsmedizin* Springer-Verlag Berlin, Heidelberg: 200 (2004).
- 60) Greinacher A, Bux J, Salama A. Autoimmune Thrombozytopenie, Neutropenie und Hämolyse. *Internist*; **50**: 276-290 (2009).
- 61) Sachs UJ, Bakchoul T, Bein G. Fetale und neonatale Alloimmunthrombozytopenie. *Transfusionsmedizin 2*: 77-89 (2010) modifiziert nach Kamphuis MM, Paridaans N, Porcelijn L et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. *Biol*; **117**: 1335-1343 (2010).
- 62) Selleng K, Greinacher A. *Intensivmedizin update 1* (2005).
- 63) Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis and management. *Br J Haematol*; **121**: 535-555 (2003).
- 64) Girolami B, Prandoni P, Stephani PM, Tanduo C, Sabbion P, Eichler P et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. *Blood*; **101**: 2955-2959 (2003).
- 65) Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med*; **344**: 1286-1292 (2001).

# Literaturhinweise

---

- 66) Deloughery T.  
*Drug-induced immune hematologic disease.*  
*Immunol Allerg Clin North Am*; **18**:829-841(1998).
- 67) Greinacher A, Pötzsch B, Amiral J.  
*Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as major antigen.*  
*Thrombosis and haemostasis*; **71**: 247-251(1994).
- 68) Greinacher A, Lubenow N, Hinz P.  
*Heparin-induzierte Thrombozytopenie.*  
*Deutsches Ärzteblatt*; **100**: A2220-A2229 (2003).